{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:14Z","timestamp":1787030114078,"version":"build-2736575974"},"reference-count":102,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen Science and Technology Program","award":["JCYJ20220530143417039"],"award-info":[{"award-number":["JCYJ20220530143417039"]}]},{"name":"Shenzhen Science and Technology Program","award":["2024A1515013185"],"award-info":[{"award-number":["2024A1515013185"]}]},{"name":"Shenzhen Science and Technology Program","award":["B2402012"],"award-info":[{"award-number":["B2402012"]}]},{"name":"Shenzhen Science and Technology Program","award":["82271789"],"award-info":[{"award-number":["82271789"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["JCYJ20220530143417039"],"award-info":[{"award-number":["JCYJ20220530143417039"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["2024A1515013185"],"award-info":[{"award-number":["2024A1515013185"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["B2402012"],"award-info":[{"award-number":["B2402012"]}]},{"name":"Guangdong Basic and Applied Basic Research Foundation","award":["82271789"],"award-info":[{"award-number":["82271789"]}]},{"name":"Shenzhen Medical Research Fund","award":["JCYJ20220530143417039"],"award-info":[{"award-number":["JCYJ20220530143417039"]}]},{"name":"Shenzhen Medical Research Fund","award":["2024A1515013185"],"award-info":[{"award-number":["2024A1515013185"]}]},{"name":"Shenzhen Medical Research Fund","award":["B2402012"],"award-info":[{"award-number":["B2402012"]}]},{"name":"Shenzhen Medical Research Fund","award":["82271789"],"award-info":[{"award-number":["82271789"]}]},{"name":"National Science Fund of China","award":["JCYJ20220530143417039"],"award-info":[{"award-number":["JCYJ20220530143417039"]}]},{"name":"National Science Fund of China","award":["2024A1515013185"],"award-info":[{"award-number":["2024A1515013185"]}]},{"name":"National Science Fund of China","award":["B2402012"],"award-info":[{"award-number":["B2402012"]}]},{"name":"National Science Fund of China","award":["82271789"],"award-info":[{"award-number":["82271789"]}]},{"name":"Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China","award":["JCYJ20220530143417039"],"award-info":[{"award-number":["JCYJ20220530143417039"]}]},{"name":"Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China","award":["2024A1515013185"],"award-info":[{"award-number":["2024A1515013185"]}]},{"name":"Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China","award":["B2402012"],"award-info":[{"award-number":["B2402012"]}]},{"name":"Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China","award":["82271789"],"award-info":[{"award-number":["82271789"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The Epstein\u2013Barr virus (EBV) is the first human herpesvirus identified as an oncogenic agent, with approximately 95% of adults worldwide being latently infected. EBV infection is associated with multiple diseases, including nasopharyngeal carcinoma, Hodgkin\u2019s lymphoma, infectious mononucleosis, and multiple sclerosis. Given significant EBV-associated disease burden, developing effective vaccines against EBV remains a priority. In this review, we first presented the current understanding of EBV biology and pathogenesis, focusing on its biological structure and immune evasion mechanisms, and discussed key viral antigens\u2014including gp350, gp42, gH\/gL, and latency proteins\u2014as potential targets for EBV vaccine development. We also summarized recent advances in various EBV vaccine platforms, including subunit, viral vector-based, nanoparticle-based, and mRNA vaccines, and discussed the related preclinical and clinical evidence, although no effective EBV vaccine has been approved for clinical use yet. In summary, this review provides an overview of the current landscape in EBV vaccine research, and sheds new light on developing new therapeutic approaches against EBV-associated diseases.<\/jats:p>","DOI":"10.3390\/v17070936","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Recent Progress in the Vaccine Development Against Epstein\u2013Barr Virus"],"prefix":"10.3390","volume":"17","author":[{"given":"Yihao","family":"Dai","sequence":"first","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botian","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Tao","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conglei","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China"},{"name":"Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen 518172, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pociupany, M., Snoeck, R., Dierickx, D., and Andrei, G. (2024). Treatment of Epstein-Barr Virus Infection in Immunocompromised Patients. Biochem. Pharmacol., 225.","DOI":"10.1016\/j.bcp.2024.116270"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e037505","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and Regional Incidence, Mortality and Disability-Adjusted Life-Years for Epstein-Barr Virus-Attributable Malignancies, 1990\u20132017","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Zhang, Q., Zhang, B., Dai, Y., Gao, Y., Li, C., Yu, Y., and Li, C. (2024). Epstein\u2013Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158160"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/cti.2014.27","article-title":"Epstein-Barr Virus Vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Eladwy, R.A., Vu, H.T., Shah, R., Li, C.G., Chang, D., and Bhuyan, D.J. (2023). The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021716"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0360-3016(00)00779-3","article-title":"Long-Term Survival of Nasopharyngeal Carcinoma Following Concomitant Radiotherapy and Chemotherapy","volume":"48","author":"Cheng","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2005.12.081","article-title":"Long-Term Survival after Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III Trials","volume":"23","author":"Chua","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/56.4.697","article-title":"Epstein-Barr Virus--Is It Time to Develop a Vaccine Program?","volume":"56","author":"Epstein","year":"1976","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41541-022-00587-6","article-title":"Urgency and Necessity of Epstein-Barr Virus Prophylactic Vaccines","volume":"7","author":"Zhong","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Escalante, G.M., Mutsvunguma, L.Z., Muniraju, M., Rodriguez, E., and Ogembo, J.G. (2022). Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.867918"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yu, H., and Robertson, E.S. (2023). Epstein\u2013Barr Virus History and Pathogenesis. Viruses, 15.","DOI":"10.3390\/v15030714"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, Virologic, and Immunologic Factors Associated with Acquisition and Severity of Primary Epstein\u2013Barr Virus Infection in University Students","volume":"207","author":"Balfour","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_13","first-page":"2603","article-title":"Epstin-Barr Virus and Its Replication","volume":"2","author":"Kieff","year":"2007","journal-title":"Fields Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14760584.2019.1605906","article-title":"Prophylactic and Therapeutic Strategies for Epstein-Barr Virus-Associated Diseases: Emerging Strategies for Clinical Development","volume":"18","author":"Dasari","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein\u2013Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/310207a0","article-title":"DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome","volume":"310","author":"Baer","year":"1984","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coviro.2013.12.001","article-title":"Epstein Barr Virus Entry; Kissing and Conjugation","volume":"4","author":"Rowe","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.4049\/jimmunol.174.11.6599","article-title":"EBV and systemic lupus erythematosus: A new perspective","volume":"174","author":"Gross","year":"2005","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molimm.2021.01.013","article-title":"Antibodies to an Epstein Barr Virus Protein That Cross-React with dsDNA Have Pathogenic Potential","volume":"132","author":"Singh","year":"2021","journal-title":"Mol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0024-3205(99)00214-3","article-title":"A Model for Persistent Infection with Epstein-Barr Virus: The Stealth Virus of Human B Cells","volume":"65","author":"Babcock","year":"1999","journal-title":"Life Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1128\/JVI.00445-07","article-title":"Epstein-Barr Virus Entry","volume":"81","year":"2007","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Connolly, S.A., Jardetzky, T.S., and Longnecker, R. (2020). The Structural Basis of Herpesvirus Entry. Nat. Rev. Microbiol., 19.","DOI":"10.1038\/s41579-020-00448-w"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, J., and Longnecker, R. (2019). Epithelial Cell Infection by Epstein\u2013Barr Virus. FEMS Microbiol. Rev., 43.","DOI":"10.1093\/femsre\/fuz023"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","article-title":"Ephrin Receptor A2 Is an Epithelial Cell Receptor for Epstein\u2013Barr Virus Entry","volume":"3","author":"Zhang","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1097-2765(02)00465-3","article-title":"Structure of the Epstein-Barr Virus Gp42 Protein Bound to the MHC Class II Receptor HLA-DR1","volume":"9","author":"Mullen","year":"2002","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1128\/jvi.61.5.1416-1420.1987","article-title":"Identification of Gp350 as the Viral Glycoprotein Mediating Attachment of Epstein-Barr Virus (EBV) to the EBV\/C3d Receptor of B Cells: Sequence Homology of Gp350 and C3 Complement Fragment C3d","volume":"61","author":"Nemerow","year":"1987","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Houen, G., and Trier, N.H. (2021). Epstein-Barr Virus and Systemic Autoimmune Diseases. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.587380"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and Lytic Replication in Epstein-Barr Virus-Associated Oncogenesis","volume":"17","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.immuni.2025.01.010","article-title":"Structural Basis for Complement Receptor Engagement and Virus Neutralization through Epstein-Barr Virus Gp350","volume":"58","author":"Joyce","year":"2025","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein Gp110 of Epstein\u2013Barr Virus Determines Viral Tropism and Efficiency of Infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T Cells Targeting Epstein-Barr Virus Gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.celrep.2013.09.012","article-title":"Spontaneous Lytic Replication and Epitheliotropism Define an Epstein-Barr Virus Strain Found in Carcinomas","volume":"5","author":"Tsai","year":"2013","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1038\/s41467-018-06889-5","article-title":"Establishment and Characterization of New Tumor Xenografts and Cancer Cell Lines from EBV-Positive Nasopharyngeal Carcinoma","volume":"9","author":"Lin","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein-Barr Virus Gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1128\/jvi.69.7.3987-3994.1995","article-title":"The Epstein-Barr Virus (EBV) BZLF2 Gene Product Associates with the gH and gL Homologs of EBV and Carries an Epitope Critical to Infection of B Cells but Not of Epithelial Cells","volume":"69","author":"Li","year":"1995","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0602-594","article-title":"Alternate Replication in B Cells and Epithelial Cells Switches Tropism of Epstein\u2013Barr Virus","volume":"8","author":"Borza","year":"2002","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1128\/JVI.72.7.5552-5558.1998","article-title":"Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL To Infect B Lymphocytes and Epithelial Cells","volume":"72","author":"Wang","year":"1998","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/JVI.79.2.841-852.2005","article-title":"Epstein-Barr Virus Gp42 Is Posttranslationally Modified To Produce Soluble Gp42 That Mediates HLA Class II Immune Evasion","volume":"79","author":"Ressing","year":"2005","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.immuni.2024.02.008","article-title":"Epstein-Barr Virus Gp42 Antibodies Reveal Sites of Vulnerability for Receptor Binding and Fusion to B Cells","volume":"57","author":"Bu","year":"2024","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e180216","DOI":"10.1172\/JCI180216","article-title":"A Large-Scale Population-Based Study Reveals That Gp42-IgG Antibody Is Protective against EBV\u2013Associated Nasopharyngeal Carcinoma","volume":"135","author":"Kong","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.1128\/JVI.00572-06","article-title":"Soluble Epstein-Barr Virus Glycoproteins gH, gL, and Gp42 Form a 1:1:1 Stable Complex That Acts like Soluble Gp42 in B-Cell Fusion but Not in Epithelial Cell Fusion","volume":"80","author":"Kirschner","year":"2006","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","article-title":"gH\/gL Supercomplexes at Early Stages of Herpesvirus Entry","volume":"18","author":"Heldwein","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pino, G.L.G.-D., and Heldwein, E.E. (2022). Well Put Together\u2014A Guide to Accessorizing with the Herpesvirus gH\/gL Complexes. Viruses, 14.","DOI":"10.3390\/v14020296"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02467-19","DOI":"10.1128\/AAC.02467-19","article-title":"Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation","volume":"64","author":"Maertens","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1006\/scbi.2001.0412","article-title":"Role of LMP1 in Immune Control of EBV Infection","volume":"11","author":"Pai","year":"2001","journal-title":"Semin. Cancer Biol."},{"key":"ref_47","first-page":"119","article-title":"The Latent Membrane Protein 1 (LMP1)","volume":"391","author":"Kieser","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pang, M.-F., Lin, K.-W., and Peh, S.-C. (2008). The Signaling Pathways of Epstein-Barr Virus-Encoded Latent Membrane Protein 2A (LMP2A) in Latency and Cancer. Cell. Mol. Biol. Lett., 14.","DOI":"10.2478\/s11658-008-0045-2"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wilson, J.B., Manet, E., Gruffat, H., Busson, P., Blondel, M., and Fahraeus, R. (2018). EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. Cancers, 10.","DOI":"10.3390\/cancers10040109"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.virol.2015.05.018","article-title":"The AT-Hook DNA Binding Ability of the Epstein Barr Virus EBNA1 Protein Is Necessary for the Maintenance of Viral Genomes in Latently Infected Cells","volume":"484","author":"Chakravorty","year":"2015","journal-title":"Virology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0092-8674(00)81056-9","article-title":"Crystal Structure of the DNA-Binding Domain of the Epstein-Barr Virus Origin-Binding Protein, EBNA1, Bound to DNA","volume":"84","author":"Bochkarev","year":"1996","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1084\/jem.191.10.1649","article-title":"Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1","volume":"191","author":"Bickham","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12088","DOI":"10.1128\/JVI.77.22.12088-12104.2003","article-title":"Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation","volume":"77","author":"Nikiforow","year":"2003","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr Virus (EBV): Biology and Clinical Disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sun, C., Chen, X., Kang, Y., and Zeng, M. (2021). The Status and Prospects of Epstein\u2013Barr Virus Prophylactic Vaccine Development. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.677027"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eado5937","DOI":"10.1126\/sciimmunol.ado5937","article-title":"Linking Vaccine Adjuvant Mechanisms of Action to Function","volume":"10","author":"Chapman","year":"2025","journal-title":"Sci. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine Adjuvants: Mechanisms and Platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2297453","DOI":"10.1080\/21645515.2023.2297453","article-title":"Toll-like Receptor Agonists as Cancer Vaccine Adjuvants","volume":"20","author":"Jeon","year":"2024","journal-title":"Human. Vaccines Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00281-017-0654-9","article-title":"Vaccine Responses in Newborns","volume":"39","author":"Saso","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00430-018-0545-2","article-title":"Vaccine Adjuvants CpG (Oligodeoxynucleotides ODNs), MPL (3-O-Deacylated Monophosphoryl Lipid A) and Naloxone-Enhanced Th1 Immune Response to the Plasmodium Vivax Recombinant Thrombospondin-Related Adhesive Protein (TRAP) in Mice","volume":"207","author":"Nazeri","year":"2018","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112073","DOI":"10.1016\/j.celrep.2023.112073","article-title":"Crosstalk between ILC2s and Th2 Cells Varies among Mouse Models","volume":"42","author":"Gurram","year":"2023","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00935-17","DOI":"10.1128\/IAI.00935-17","article-title":"The Adjuvant Bordetella Colonization Factor A Attenuates Alum-Induced Th2 Responses and Enhances Bordetella Pertussis Clearance from Mouse Lungs","volume":"86","author":"Quataert","year":"2018","journal-title":"Infect. Immun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine Adjuvants: Understanding the Structure and Mechanism of Adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2300086","DOI":"10.1002\/adma.202300086","article-title":"Tumor-Specific Photothermal-Therapy-Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles","volume":"35","author":"Liu","year":"2023","journal-title":"Adv. Mater."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/08830185.2013.773326","article-title":"Particulate Adjuvant and Innate Immunity: Past Achievements, Present Findings, and Future Prospects","volume":"32","author":"Kuroda","year":"2013","journal-title":"Int. Rev. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vetimm.2016.02.017","article-title":"A Preventive Immunization Approach against Insect Bite Hypersensitivity: Intralymphatic Injection with Recombinant Allergens in Alum or Alum and Monophosphoryl Lipid A","volume":"172","author":"Jonsdottir","year":"2016","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s10787-023-01233-w","article-title":"Anti-Arthritic Effects of Geranium Essential Oil Loaded Chitosan Nanoparticles in Freund\u2019s Complete Adjuvant Induced Arthritic Rats through down-Regulation of Inflammatory Cytokines","volume":"31","author":"Naseer","year":"2023","journal-title":"Inflammopharmacol"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acsnano.0c08379","article-title":"Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.jvacx.2024.100438","article-title":"BpOmpW Antigen Administered with CAF01 Adjuvant Stimulates Comparable T Cell Responses to Sigma Adjuvant System","volume":"17","author":"Quinn","year":"2024","journal-title":"Vaccine X"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.xcrm.2024.101587","article-title":"Vaccination with Nanoparticles Displaying gH\/gL from Epstein-Barr Virus Elicits Limited Cross-Protection against Rhesus Lymphocryptovirus","volume":"5","author":"Edwards","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/j.gastro.2020.01.045","article-title":"Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease","volume":"158","author":"Freitag","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/ACI.0000000000000782","article-title":"Nanoparticles in Allergen Immunotherapy","volume":"21","author":"Longo","year":"2021","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/irv.12697","article-title":"Nanoparticles in Influenza Subunit Vaccine Development: Immunogenicity Enhancement","volume":"14","author":"Chua","year":"2020","journal-title":"Influenza Resp. Viruses"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., and Xu, M. (2023). Research Advances on the Stability of mRNA Vaccines. Viruses, 15.","DOI":"10.3390\/v15030668"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cui, X., and Snapper, C.M. (2021). Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.734471"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II Studies to Evaluate Safety and Immunogenicity of a Recombinant Gp350 Epstein-Barr Virus Vaccine in Healthy Adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tanner, J.E., Hu, J., and Alfieri, C. (2018). Construction and Characterization of a Humanized Anti-Epstein-Barr Virus Gp350 Antibody with Neutralizing Activity in Cell Culture. Cancers, 10.","DOI":"10.3390\/cancers10040112"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant Gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children with Chronic Kidney Disease Awaiting Transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/j.1460-2075.1985.tb04070.x","article-title":"Recombinant Vaccinia Virus Induces Neutralising Antibodies in Rabbits against Epstein-Barr Virus Membrane Antigen Gp340","volume":"4","author":"Mackett","year":"1985","journal-title":"EMBO J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7","article-title":"Immunisation of Common Marmosets with Vaccinia Virus Expressing Epstein-Barr Virus (EBV) Gp340 and Challenge with EBV","volume":"50","author":"Mackett","year":"1996","journal-title":"J. Med. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890250209","article-title":"Recombinant Vaccinia Virus Expressing Epstein-Barr Virus Glycoprotein Gp340 Protects Cottontop Tamarins against EB Virus-Induced Malignant Lymphomas","volume":"25","author":"Morgan","year":"1988","journal-title":"J. Med. Virol."},{"key":"ref_84","first-page":"171","article-title":"First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev. Biol. Stand."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox Vaccine: The Good, the Bad, and the Ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.2741\/3126","article-title":"Epstein-Barr Virus Vaccine Development: A Lytic and Latent Protein Cocktail","volume":"13","author":"Lockey","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.7150\/thno.42494","article-title":"A Novel Vaccine Candidate Based on Chimeric Virus-like Particle Displaying Multiple Conserved Epitope Peptides Induced Neutralizing Antibodies against EBV Infection","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB Nanoparticle Vaccine Elicits a Protective Neutralizing Antibody Response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/s41467-024-49546-w","article-title":"A Cocktail Nanovaccine Targeting Key Entry Glycoproteins Elicits High Neutralizing Antibody Levels against EBV Infection","volume":"15","author":"Zhong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Li, P., Jiang, Z., Shi, J., Sha, H., Yu, Z., Zhao, Y., Han, S., and Ma, L. (2025). A Self-Assembled Nanoparticle Vaccine Elicits Effective Neutralizing Antibody Response against EBV Infection. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1530364"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","article-title":"Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice","volume":"14","author":"Dasari","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Larijani, A., Kia-Karimi, A., and Roostaei, D. (2023). Design of a Multi-Epitopic Vaccine against Epstein-Barr Virus via Computer-Based Methods. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1115345"},{"key":"ref_94","first-page":"9363750","article-title":"Computer-Aided Design of an Epitope-Based Vaccine against Epstein-Barr Virus","volume":"2017","author":"Lafuente","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.genrep.2025.102137","article-title":"Comprehensive Immunoinformatics and Structural Biology Based Design for Novel Peptide Vaccines against Epstein-Barr Virus","volume":"38","author":"Naz","year":"2025","journal-title":"Gene Rep."},{"key":"ref_96","unstructured":"(2025, May 15). Our Story. Available online: https:\/\/www.modernatx.com\/en-US\/about-us\/our-story?."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The Clinical Progress of mRNA Vaccines and Immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2302116","DOI":"10.1002\/advs.202302116","article-title":"mRNA-based Vaccines Targeting the T-cell Epitope-rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti-Tumor Immunity in Mice","volume":"10","author":"Zhao","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/(SICI)1097-0215(19981023)79:5<481::AID-IJC6>3.0.CO;2-X","article-title":"The Epstein-Barr Virus (EBV) Major Envelope Glycoprotein Gp350\/220-Specific Antibody Reactivities in the Sera of Patients with Different EBV-Associated Diseases","volume":"79","author":"Xu","year":"1998","journal-title":"Int. J. Cancer"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:01:55Z","timestamp":1760032915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/7\/936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":102,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["v17070936"],"URL":"https:\/\/doi.org\/10.3390\/v17070936","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}